Education
About Us
Working with TipRanks
Follow Us
Bluejay Diagnostics, Inc. (BJDX)
:BJDX
RESEARCH TOOLSreports
Top Page
Bluejay Diagnostics
(NASDAQ:BJDX)
26Underperform
Bluejay Diagnostics (BJDX) vs. S&P 500 (SPY)
Market Cap
$1.80M
Dividend YieldN/A
Average Volume (3M)51.88K
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue GrowthN/A
EPS Growth63.82%
CountryUS
Employees10
SectorHealthcare
Sector Strength62
IndustryMedical - Devices
Share Statistics
EPS (TTM)-685.13
Shares Outstanding554,012
10 Day Avg. Volume33,855
30 Day Avg. Volume51,882
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bluejay Diagnostics Business Overview & Revenue Model
Company DescriptionBluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
How the Company Makes MoneyBluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.
Bluejay Diagnostics Financial Statement Overview
Summary
Bluejay Diagnostics is struggling financially with substantial net losses and negative cash flows, despite having a solid equity position and low leverage.Income Statement
Bluejay Diagnostics has shown some revenue growth in the TTM period, achieving a Gross Profit Margin of 88.67%. However, the company is experiencing substantial net losses, with a Net Profit Margin of -592.82% and negative EBIT and EBITDA margins, indicating significant operating challenges.30
Negative
Balance Sheet
The company has a strong equity base, with an Equity Ratio of 85.76%, but the Return on Equity is negative due to net losses. The Debt-to-Equity Ratio is low at 0.03, suggesting low leverage, but ongoing losses may erode equity over time.40
Negative
Cash Flow
Operating and Free Cash Flows are both negative, with a significant gap between cash flows and net income, indicating liquidity challenges. The Operating Cash Flow to Net Income Ratio is 1.03, reflecting cash outflow issues.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.45M | 0.00 | 249.04K | 0.00 | 0.00 | 0.00 | Gross Profit |
| 1.28M | -780.96K | 48.91K | -145.72K | -157.04K | -142.97K | EBIT |
| -8.07M | -10.31M | -9.32M | -3.23M | -1.20M | -1.63M | EBITDA |
| -7.77M | -9.17M | -8.99M | -3.08M | -1.04M | -1.49M | Net Income Common Stockholders |
| -8.59M | -9.95M | -9.23M | -3.73M | -1.13M | -757.72K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 96.01K | 2.21M | 10.11M | 19.05M | 912.36K | 96.01K | Total Assets |
| 0.00 | 4.87M | 13.52M | 21.02M | 1.52M | 916.52K | Total Debt |
| 0.00 | 352.98K | 492.62K | 0.00 | 1.06M | 1.07M | Net Debt |
| 96.01K | -1.86M | -9.62M | -19.05M | 143.55K | 973.28K | Total Liabilities |
| 0.00 | 1.97M | 1.98M | 637.16K | 5.72M | 3.85M | Stockholders Equity |
| -464.31K | 2.89M | 11.54M | 20.38M | -4.21M | -2.93M |
| Cash Flow | Free Cash Flow | ||||
| -9.25M | -9.02M | -8.94M | -4.39M | -508.71K | -1.70M | Operating Cash Flow |
| -8.86M | -8.31M | -7.74M | -4.37M | -508.71K | -1.69M | Investing Cash Flow |
| -393.55K | -704.17K | -1.20M | -23.95K | 0.00 | -6.02K | Financing Cash Flow |
| 9.93M | 1.11M | 8.07K | 22.53M | 1.33M | 1.51M |
Bluejay Diagnostics Technical Analysis
Negative
3.70
Price Trends
3.84
Negative
3.92
Negative
13.88
Negative
Market Momentum
-0.04
Positive
43.10
Neutral
20.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 3.7 is below the 20-day moving average (MA) of 3.93, below the 50-day MA of 3.84, and below the 200-day MA of 13.88, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.
Bluejay Diagnostics Risk Analysis
Bluejay Diagnostics disclosed 52 risk factors in its most recent earnings report. Bluejay Diagnostics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bluejay Diagnostics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $248.34M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $2.30B | ― | -50.74% | ― | -7.03% | -20233.78% | |
43 Neutral | $433.42M | ― | -166.29% | ― | 0.37% | -20.49% | |
35 Underperform | $3.10M | ― | 366.81% | ― | -30.19% | 97.74% | |
30 Underperform | $50.07M | ― | 138.92% | ― | 59.10% | 37.59% | |
26 Underperform | $1.80M | ― | -178.98% | ― | ― | 63.82% |
* Healthcare Sector Average
Performance Comparison
BJDX
Bluejay Diagnostics
3.25
-279.75
-98.85%
OSUR
Orasure Technologies
3.22
-2.79
-46.42%
QDEL
QuidelOrtho
32.49
-10.19
-23.88%
TTOO
T2 Biosystems
0.12
-2.74
-95.80%
VNRX
VolitionRX
0.56
-0.20
-26.32%
SENS
Senseonics Holdings
0.62
0.13
26.53%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.